Please login to the form below
irritable bowel syndrome
This page shows the latest irritable bowel syndrome news and features for those working in and with pharma, biotech and healthcare.
Mallinckrodt pays $1.2bn for Sucampo Pharma
Amitizia is the prize asset in the deal, with FDA approvals in hand for three indications - chronic idiopathic constipation as well as constipation linked to irritable bowel syndrome and chronic opioid
Latest news
-
NICE backs Allergan's IBS therapy Truberzi
NICE has recommended routine NHS funding for Allergan's Truberzi, which is the first drug for irritable bowel syndrome with diarrhoea (IBS-D) to pass through its review process.
-
FDA approves Synergy's constipation drug Trulance
In trials, a once-daily dose of Trulance was more effective than placebo to improve the frequency of bowel movements in patients diagnosed with CIC for at least six months. ... constipation linked to irritable bowel syndrome (IBS).
-
Valeant's proposed sale of Salix to Takeda 'in jeopardy'
Now, the Canadian company has decided to build up Salix' salesforce to push its flagship brand – Xifaxan (rifaximin) for diarrhoea caused by irritable bowel syndrome – which has been tipped by some
-
HIV prevention pill heads July CHMP recommendations
Other positive recommendations were given for Aptalis' Truberzi (eluxadoline) as a treatment for irritable bowel syndrome with diarrhoea, along with two biosimilar versions of Sanofi's clot-busting drug Lovenox (enoxaparin) -
-
Ferring signs telemedicine collaboration with Danish hospital
Ferring Pharmaceuticals has signed a telemedicine deal with a Copenhagen hospital that it hopes will transform patient care in inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS).
More from news
Approximately 1 fully matching, plus 50 partially matching documents found.
Latest Intelligence
-
Erectile dysfunction, constipation, vaginal dryness and other laughing matters
An Irritable Bowel Syndrome campaign tackled the challenge of IBS not being taken seriously by actually using humour. ... This campaign showed doctors suffering from Irritable Disbelief Syndrome (IDS) - a brave move but exactly the perception shift
-
Taking a lean and careful approach
His pioneering research culminated in the drug, Trulance, which has received FDA approval and is being used to treat irritable bowel syndrome and chronic constipation. ... ulcerative colitis, type 1 diabetes and inflammatory bowel disease.
-
Can biosimilars live up to the hype?
She is convinced that biosimilars are essential in treating patients with chronic conditions such as rheumatoid arthritis, irritable bowel syndrome and psoriasis, because they provide the same uplift in quality of
-
Oral biologics delivery still elusive
years. Among a newer generation of orally-delivered peptides is Ironwood Pharma's peptide drug Linzess/Constella (linaclotide) - which debuted in 2012 for constipation associated with irritable bowel syndrome. ... Among these are Avaxia Biologics, which
-
Pharma deals during April 2014
associated with nephrotic syndrome, certain rheumatology-related conditions, and infantile spasms. ... Eluxadoline is a first-in-class, locally-acting mu opioid receptor agonist/ delta opioid receptor antagonist for treating symptoms of
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Ironwood appoints Edward Owens to board
irritable bowel syndrome and constipation. “
-
Ironwood promotes Dr Mark Currie
Linaclotide was approved as a treatment for irritable bowel syndrome last year by regulators in Europe, where the drug is marketed as Constella by Almirall.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Featured jobs
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Senior Account Manager / Account Director
-
Great salary and bebefits
-
Senior Medical Writer
-
Great salary and bebefits
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
-
Senior Medical Writer
-
Great salary and benefits
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Account Manager – Med Comms – London
-
Salary TBC
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
-
Scientific Director
-
Great salary and bebefits
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
-
Senior Programme Executive
-
Salary TBC
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
Subscribe to our email news alerts
PMHub
SpotMe
SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...
Latest intelligence
- Pharma’s isolated islands of innovation
- With service design and technology often failing the patient, why perspective on improving outcomes need to change...
- Uncertainty, austerity and Brexit
- What does it mean for the life science sector?...
- The Holy Grail of HCP Access
- This is the data you need to gain access....
Quick links
Infographics
